Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric Cancer in a Real-World Setting: A Nationwide Cohort Study
Patients treated with T-DXd for HER2+ mG/GEJ cancer in the real world showed lower outcomes than those in pivotal clinical trials, consistent with previous reports on accelerated approvals.
Authors
- Nadia Haddy (ORCID: https://orcid.org/0000-0001-9316-8280)
- Mahmoud Zureik (ORCID: https://orcid.org/0000-0002-8393-4217)
- Hugo Jourdain (ORCID: https://orcid.org/0000-0001-8035-7517)
- Adrien Monard (ORCID: https://orcid.org/0000-0001-6485-4951)
- David Desplas (ORCID: https://orcid.org/0000-0003-1151-3867)
- Nicolas Albin (ORCID: https://orcid.org/0000-0003-0466-0068)
Institutions
- Conservatoire National des Arts et Métiers (FR)
- Inserm (FR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Université Paris-Saclay (FR)
- Centre de recherche en Epidémiologie et Santé des Populations (FR)
- Agence Nationale de Sécurité du Médicament et des Produits de Santé (FR)
- Groupe Hospitalier Mutualiste de Grenoble (FR)
- Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail (FR)
Publication Details
- Journal
- Clinical and Translational Gastroenterology
- Published
- 2024-10-07
- DOI
- https://doi.org/10.14309/ctg.0000000000000773
- Citations
- 1
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.42